13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • SPARTA

    Acronym: 

    SPARTA

    ACTRN/NCT /ethics: 

    NCT03175224

    Scientific title: 

    APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

    Summary of trial and patient characteristics

    Cancer Type Lung & mesothelioma, All cancers
    Trial Type Treatment
    Phase Phase I, Phase II Tumour Stream Non-small cell lung cancer
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date 2017-09-27
    Molecular Target Anticipated End Date 2021-12-30
    Cancer Type Lung & mesothelioma, All cancers
    Trial Type Treatment
    Phase Phase I, Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Non-small cell lung cancer
    Cancer Stage All stages
    Anticipated Start Date 2017-09-27
    Anticipated End Date 2021-12-30

    Trial Summary

    The primary Phase 1 purpose of this study is to assess overall safety and tolerability and recommended Phase 2 dose (RP2D) of APL-101. The Phase 2 portion will assess efficacy of the dose determined in Phase 1 in individuals with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

    Lay Summary

    APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

    Sponsor / Cooperative group

    Apollomics Inc.

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Dr Chris Karapetis Not Yet Recruiting